Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins

American Journal of Cardiovascular Drugs

Volumn 9, Issue 2, 2009, Pages 109-115

  Ferrires, Jean ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; AVASIMIBE; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 63849329662     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200909020-00005     Document Type: Review

References (44)

1. European mortality database [online database]. Copenhagen: WHO Regional Office for Europe, 2007 [online]. Available from URL: http://www.euro.who.int/ InformationSources/Data/20011017-1 [Accessed 2009 Feb 26]
2. National Institute for Statistics and Economic Studies (INSEE). France in facts and figures: main causes of death. 2008 [online]. Available from URL: http://www.insee.fr/fr/themes/tableau.asp?reg-id=0&ref-id= NATFPS06205[Accessed 2009 Feb 26]
3. National Institute for Health and Clinical Excellence. Technology Appraisal 94: statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease [online]. Available from URL: http://www.nice.org.uk/ Guidance/TA94 [Accessed 2009 Feb 26]
4. Kruth HS. Lipoprotein cholesterol and atherosclerosis. Curr Mol Med 2001 Dec; 1 (6): 633-53
5. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007 Jan; 14 (1): 55-61
6. NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-421
7. Gordon D, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15
8. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol lower risk of ischemic heart disease? BMJ 1994; 308: 367-72
9. Saini HK, Xu YJ, Arneja AS, et al. Pharmacological basis of different targets for the treatment of atherosclerosis. J CellMol Med 2005 Oct-Dec; 9 (4): 818-39
10. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43
11. Tuzcu EM, Nicholls SJ. Statins: targeting inflammation by lowering lowdensity lipoprotein. J Am Coll Cardiol 2007; 49 (20): 2010-2
12. Sankatsing RR, de Groot E, Jukema JW, et al. Surrogate markers for atherosclerotic disease. Curr Opin Lipidol 2005 Aug; 16 (4): 434-41
13. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the advisory board of the 3rd and 4th Watching the Risk Symposium 13th and 15th European stroke conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23 (1): 75-80
14. Bisoendial RJ, Hovingh GK, de Groot E, et al. Measurement of subclinical atherosclerosis: beyond risk factor assessment. Curr Opin Lipidol 2002 Dec; 13 (6): 595-603
15. StaubD,MeyerhansA, Bundi B, et al. Prediction of cardiovascularmorbidity andortality: comparison of the internal carotid artery resistive index with the common carotid artery intima-media thickness. Stroke 2006 Mar; 37 (3): 800-5
16. Berry C, L'Allier PL, Gregoire J, et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 2008; 115: 1851-7
17. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr 5; 295 (13): 1556-65
18. Brown BG, Zhao X-Q. Is intravascular ultrasound the gold standard surrogate for clinically relevant atherosclerosis progression? J Am Coll Cardiol 2007; 49 (9): 933-8
19. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 Mar 3; 291 (9): 1071-80
20. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul 13; 110 (2): 227-39
21. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 2009 Jan; 157 (1): 111-7.e2
22. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360 (9326): 7-22
23. Patel T, Usmani A, Bavry A, et al. Relationship between intensive statin therapy and cardiovascular outcomes in patients with stable coronary artery disease: ameta-analysis of randomized clinical trials. J AmColl Cardiol 2007; 49 (9 Suppl. A): 245
24. Brown BG, Stukovsky KH, Zhao X-Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease preventionwith various drug classes, and their combinations: a meta-analysis of 23 randomized trials. Curr Opin Lipidol 2006; 17: 631-6
25. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997 May; 32 (5): 403-25
26. Bulbulia R, Bowman L, Wallendszus K. MRC/BHF Heart Protection Study (HPS): mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 393
27. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 Jun 28; 326 (7404): 1423
28. Balamuthusamy S, Molnar J, Adigopula S. Statins decrease the risk of acute myocardial infarction and coronary heart disease mortality in patients with renal failure. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 188-9
29. Saha S, Saremi A, Velasquez-Cecena J-L. Statins reduce the risk of death and the occurrence of adverse cardiovascular events in patients with dyslipidemia and renal dysfunction: a meta-analysis of randomized placebo-controlled trials. Am J Cardiol 2007; 49 (9 Suppl. A): 344
30. Brown BG, Zhao X-Q, Sacco DE, et al. Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events. Br Heart J 1993; 69 Suppl.: S48-53
31. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119 (10): 966-76
32. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995 Dec; 6 (6): 386-8
33. Ballantyne CM, Herd JA, Dunn JK, et al. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 1997 Dec; 8 (6): 354-61
34. Ballantyne CM, Raichlen JS, Nicholls SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasoundderived coronary atheroma burden. Circulation 2008; 117: 2458-66
35. Crouse J, Grobbee D, O'Leary D, on behalf of the METEOR Study Group. Rosuvastatin arrests progression of carotid intima media thickness in low risk individuals: main results of the METEOR study. Am J Cardiol 2007; 49 (9 Suppl. A): 392-3
36. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297 (5): 499-508
37. O'Keefe Jr JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004 Jun 2; 43 (11): 2142-6
38. Nicholls SJ, Sipahi I, Crowe T. Baseline lipid status does not influence the promotion of coronary atheroma regression in response to use of high dose statin therapy: insights from ASTEROID. Am J Cardiol 2007; 49 (9 Suppl. A): 365
39. Sipahi I, Tuzcu M, Nicholls SJ. Regression of coronary atherosclerosis during treatment with statins: does age make a difference? Am J Cardiol 2007; 49 (9 Suppl. A): 336
40. Takashima H, Asai K, Wakita Y. Impact of HMG-CoA reductase inhibitors (statins) on new cardiovascular events following coronary intervention and on the progression-regression of coronary atherosclerotic plaque: a three-dimensional intravascular ultrasound study. Am J Cardiol 2007; 49 (9 Suppl. A): 325
41. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008; 94: 706-14
42. Nicholls SJ, Tuzcu EM, Sipahi I. Statin-mediated increases in HDL cholesterol promote regression of coronary atherosclerosis: insights from intravascular ultrasound. Am J Cardiol 2007; 49 (9 Suppl. A): 365
43. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Engl J Med 2005; 352 (1): 29-38
44. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein. J AmColl Cardiol 2007; 49 (20): 2003-9